Partnering in Central Nervous System Diseases

Boehringer Ingelheim

Our goal is to discover and develop breakthroughs in animal health for diseases with significant unmet need. To achieve this, we're investing in cutting-edge science and technology to expand and accelerate our drug discovery for the next generation of treatments and preventive therapies. Our research approach in central nervous system diseases focuses on targeting high unmet needs across a range of disorders. We are also leveraging synergies with our human pharma colleagues to explore common pathological and clinical features.

Collaborations with innovative and entrepreneurial partners are helping solve the biggest challenges in animal health. We believe that by working together we can bring critical diversity to innovation and accelerate the next wave of therapeutics that will transform the health and well-being of animals now and in generations to come.

Partnering Interests

Actively pursuing new partnerships in our research focus areas and open to a variety of partnership models to explore:

- Non-sedating, rapid onset anxiety and impulse control assets for dogs, cats and horses, with low risk of disinhibition and low potential for human misuse
- Cognitive function assets with palliative or disease-modifying potential for dogs
- Novel models to demonstrate efficacy in the target species.

Research Focus

- Unmet needs in cognitive dysfunction and anxiety, particularly on therapies with high efficacy and low incidence of adverse events.
- Novel diagnostics for early detection of cognitive decline.

SCAN ME

Collaboration Driving Innovation

- Growing our global community of innovation partners
- Multiple collaborations advancing new therapies
- Long-term partnerships for the next generation of breakthroughs

Investing in Animal Health Innovation

450+ million EUR
R&D for new medicines

Global
R&D presence in Europe, N. America, Asia

~1,200
staff in R&D facilities worldwide

>250
innovation collaborations

Leveraging Synergies with Human Pharma

Exchanging scientific knowledge and expertise

Access to data, models and back-up compounds

Meet the Team

Kate Christmas
kathryn.christmas@boehringer-ingelheim.com

Date of preparation: May 2023